Paper Details

  1. Home
  2. Paper Details

The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.

Author: CooperKeith, HarrisPetra, PicotJoanna, RoseMicah, ShepherdJonathan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Juvenile idiopathic arthritis (JIA) is a condition that causes joint pain, swelling, and limited movement in children. Treatment often involves medications called disease-modifying antirheumatic drugs (DMARDs) like methotrexate. Newer medications, called biologic DMARDs, are now commonly used when appropriate.
Paper Details　
Original Abstract of the Article :
Juvenile idiopathic arthritis (JIA) is characterised by joint pain, swelling and a limitation of movement caused by inflammation. Subsequent joint damage can lead to disability and growth restriction. Treatment commonly includes disease-modifying antirheumatic drugs (DMARDs), such as methotrexate. C...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867422/

データ提供：米国国立医学図書館（NLM）

Clinical Effectiveness and Cost-Effectiveness of Biologic DMARDs for Juvenile Idiopathic Arthritis

This research examines the clinical effectiveness and cost-effectiveness of four biologic disease-modifying antirheumatic drugs (DMARDs) - abatacept, adalimumab, etanercept, and tocilizumab - for treating juvenile idiopathic arthritis (JIA). The study employs a systematic review and economic evaluation approach, synthesizing evidence from multiple studies to assess the benefits and costs associated with these medications. The primary objective is to provide a comprehensive evaluation of the clinical and economic value of these biologic DMARDs in the management of JIA.

Biologic DMARDs Show Promise for JIA Treatment

The review found that all four biologic DMARDs demonstrated clinical effectiveness in reducing disease activity and improving functional outcomes in JIA patients. However, there were variations in their cost-effectiveness, with tocilizumab emerging as the most cost-effective option. These findings provide valuable information for clinicians making treatment decisions for JIA patients.

Implications for JIA Treatment and Resource Allocation

This study's findings have important implications for the treatment of JIA and for healthcare resource allocation. The review highlights the importance of considering both clinical effectiveness and cost-effectiveness when selecting treatment options for JIA patients. The information provided can help guide clinicians towards choosing the most appropriate and cost-effective treatment for their patients.

Dr.Camel's Conclusion

Imagine a camel navigating a sand dune, carefully choosing each step to avoid injury. Just like this camel needs a careful balance of strength and flexibility, children with JIA require a well-considered approach to treatment. This research provides valuable insights into the effectiveness and cost-effectiveness of different biologic DMARDs, helping healthcare professionals choose the most appropriate path towards recovery for their young patients.

Date :
  1. Date Completed 2018-03-12
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27135404

DOI: Digital Object Identifier

PMC4867422

Related Literature

Article Analysis
・Effective treatment of arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.